Revisiting Seamless 2/3 Trial for GLP-1 Agonist
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Revisiting Seamless 2/3 Trial for GLP-1 Agonist
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
In this episode of "In the Interim..." we revisit the ground-breaking seamless phase 2/3 clinical trial for the GLP-1 agonist, dulaglutide—better known as Trulicity. We discuss the intricacies of the adaptive trial design, and the unique features that helped expedite development by 12-18 months. Listeners will gain insight into how Bayesian algorithms and innovative statistical methods were pivotal in navigating a complex trial design, benefiting Eli Lilly's pipeline and changing the landscape of diabetes treatment.
Key Highlights:
- Outline of the trial design and the barriers faced during its inception in 2007-2008.
- Explanation of the Clinical Utility Index and its role in adaptive randomization.
- The DSMB's role and interaction with Bayesian decision-making models.
- Simulation-based design to optimize development efficiencies.
- Insights into the predictive power of the trial on weight loss outcomes in subsequent trials.
Quotes:
- "The trial was run entirely by Bayesian algorithms." – Scott Berry
- "They believed this utility function was absolutely the right way to go forward." – Scott Berry
Ce que les auditeurs disent de Revisiting Seamless 2/3 Trial for GLP-1 Agonist
Moyenne des évaluations de clientsÉvaluations – Cliquez sur les onglets pour changer la source des évaluations.
Il n'y a pas encore de critiques pour ce titre.